Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

August 25, 2005 09:23 ET

Swiss Medica Announces Insider Buying Plan

TORONTO, ONTARIO--(CCNMatthews - Aug. 25, 2005) - Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that Swiss Medica's senior management team and members of Swiss Medica's Board of Directors intend to purchase on the open market, shares of the Company's publicly traded Class A common stock, based on their assessment of prevailing market prices. Whether any such purchases are made, and the number of shares purchased, will depend upon the availability of shares at acceptable market prices. All trades will comply with Swiss Medica's insider trading policy and insiders will file Form 4s with the S.E.C. as purchases are completed.

Mr. Raghu Kilambi, Swiss Medica's CEO commented, "At current levels, we believe our stock is undervalued. These planned open market purchases illustrate our confidence in Swiss Medica's underlying business strategy."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com

Swiss Medica's flagship product, the O24™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24™ Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24™ Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia™ and to order the product online.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    or
    Fusion Communications
    Public Relations Contact:
    Dean Mailey
    (604) 218-6767
    dean@fusioncom.ca
    or
    Stern & Co.
    Financial Media Contact:
    Stan Froelich - VP, Media Relations
    (212) 888-0044
    sfroelich@sternco.com